Stockreport

Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

Alzamend Neuro, Inc.  (ALZN) 
PDF Data confirm the positive topline results announced in June 2023 identifying a maximum tolerated dose as assessed by an independent safety review committeeIdentified dos [Read more]